However, the PET metrics of those patients were in line with the rest of the ESFT group, whilst the patient with the CIC-DUX4 mutation survived for 19 months (equal to the median OAS of the ESFT group with an interquartile range of 11–62 months) with this more aggressive tumor biology. This evidence concerns the gene DUX4 and neoplasm.